Marc Antoine Aimé

Autologous platelet rich plasma (A-PRP) combined with pelvic floor muscle training for the treatment of female stress urinary incontinence (SUI): A randomized control

par Marc Antoine Aimé | Oct 2, 2026 | Clinical Study gynecology

Stress urinary incontinence Saraluck 2023 Autologous platelet rich plasma (A-PRP) combined with pelvic floor muscle training for the treatment of female stress urinary incontinence (SUI): A randomized control clinical trial. Clinical evidence · Gynaecology There is...

Value of injection of plasma-rich platelets in the vaginal mucosa in cases with vulvovaginal atrophy: a prospective double-blinded randomized controlled study

par Marc Antoine Aimé | Oct 2, 2026 | Clinical Study gynecology

Postmenopausal vulvovaginal atrophy Hamid 2025 Value of injection of plasma-rich platelets in the vaginal mucosa in cases with vulvovaginal atrophy: a prospective double-blinded randomized controlled study. Clinical evidence · Gynaecology There is growing interest in...

Experience in management of patients with lichen sclerosus and HPV infection of the vulva

par Marc Antoine Aimé | Oct 1, 2026 | Clinical Study gynecology

Lichen sclerosus Chernova 2016 Experience in management of patients with lichen sclerosus and HPV infection of the vulva Clinical evidence · Gynaecology There is growing interest in the use of several innovative technologies being routinely used for facial skin care...

Regenlab news article

par Marc Antoine Aimé | Août 17, 2026 | Corporate

The Future of Regenerative Medicine: Regen Lab CEO Antoine Turzi in Conversation with SmartTRAK ; Regen lab CEO Antoine Turzi discusses the evolution of regenerative medicine and the company's research focus in interview with SmartTRAK 3 Regenlab founder and...

BioBridge Foundation launches the UK & Northern Europe educational season 2026-2027

par Marc Antoine Aimé | Juil 24, 2026 | Congress

BioBridge Foundation launches the UK & Northern Europe educational season 2026-2027 Focus on scientific exchange, selective clinical education and evidence-aware implementation BioBridge Foundation is introducing a UK & Northern Europe educational season from...

« Entrées précédentes



RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.



RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

CM-OA

CM-Skin



RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.



RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).



RegenWound

RegenWound is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardised and reproducible approach for clinical use.



Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.



Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.



Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.